Patents by Inventor Theodore J. Lampidis

Theodore J. Lampidis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mannose derivatives for killing tumor cells
    Patent number: 8242167
    Abstract: A method for treating cancer by killing selected tumor cells such as human breast, non-small cell lung cancer cells, pancreatic cancer cells, osteosarcoma cancer cells, and glioblastoma cells, includes administering to a patient in need of treatment, an effective amount of at least one mannose analog such as 2-DG or 2-FM or 2-CM. The killing is believed to be due to an interference with glycosylation. A theranostic method includes determining whether a patient. cancer tumor sample comprises cells sensitive to killing to at least one mannose analog due to an interference with glycosylation.
    Type: Grant
    Filed: February 26, 2007
    Date of Patent: August 14, 2012
    Assignee: University of Miami
    Inventors: Theodore J. Lampidis, Metin Kurtoglu, Johnathan C. Maher
  • TREATMENT USING CONTINUOUS LOW DOSE APPLICATION OF SUGAR ANALOGS
    Publication number: 20110183926
    Abstract: Methods and uses of low dosage nonmetabolizable D-glucose analogs and mannose analogs such as 2-deoxy-D-glucose, 5-thio-D-glucose, 2-fluoro-2-deoxy-D-glucose, 2-chloro-2-deoxy-D-glucose, 2-bromo-2-deoxy-D-glueose, 2-deoxy-2-fluoro-mannose, 2-deoxy-2-chloro-mannose, 3-deoxy mannose, 4-deoxy mannose, and 2,3 didioxy mannose, for the treatment of tumors.
    Type: Application
    Filed: May 26, 2009
    Publication date: July 28, 2011
    Applicant: UNIVERSITY OF MIAMI
    Inventors: Theodore J. Lampidis, Metin Kurtoglu
  • MANNOSE DERIVATIVES FOR KILLING TUMOR CELLS
    Publication number: 20090221698
    Abstract: A method for treating cancer by killing selected tumor cells such as human breast, non-small cell lung cancer cells, pancreatic cancer cells, osteosarcoma cancer cells, and glioblastoma cells, includes administering to a patient in need of treatment, an effective amount of at least one mannose analog such as 2-DG or 2-FM or 2-CM. The killing is believed to be due to an interference with glycosylation. A theranostic method includes determining whether a patient. cancer tumor sample comprises cells sensitive to killing to at least one mannose analog due to an interference with glycosylation.
    Type: Application
    Filed: February 26, 2007
    Publication date: September 3, 2009
    Applicant: University of Miami
    Inventors: Theodore J. Lampidis, Metin Kurtoglu, Jonathan C. Maher
  • Cancer treatment including glycolytic inhibitors
    Patent number: 7338940
    Abstract: Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: March 4, 2008
    Inventors: Theodore J. Lampidis, Waldemare Priebe
  • Cancer treatment including glycolytic inhibitors
    Patent number: 7160865
    Abstract: Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: January 9, 2007
    Inventors: Theodore J. Lampidis, Waldemore Priebe
  • Cancer chemotherapy with 2-deoxy-D-glucose
    Patent number: 6670330
    Abstract: A class of glycolytic inhibitors is useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.
    Type: Grant
    Filed: May 1, 2000
    Date of Patent: December 30, 2003
    Inventors: Theodore J. Lampidis, Waldemare Priebe
  • Cancer treatment including glycolytic inhibitors
    Publication number: 20030181393
    Abstract: Glycolytic inhibitors are useful in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.
    Type: Application
    Filed: March 28, 2003
    Publication date: September 25, 2003
    Inventors: Theodore J. Lampidis, Waldemare Priebe